320 related articles for article (PubMed ID: 22538822)
1. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism.
Thangavelu K; Pan CQ; Karlberg T; Balaji G; Uttamchandani M; Suresh V; Schüler H; Low BC; Sivaraman J
Proc Natl Acad Sci U S A; 2012 May; 109(20):7705-10. PubMed ID: 22538822
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
[TBL] [Abstract][Full Text] [Related]
3. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).
Robinson MM; McBryant SJ; Tsukamoto T; Rojas C; Ferraris DV; Hamilton SK; Hansen JC; Curthoys NP
Biochem J; 2007 Sep; 406(3):407-14. PubMed ID: 17581113
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for exploring the allosteric inhibition of human kidney type glutaminase.
Ramachandran S; Pan CQ; Zimmermann SC; Duvall B; Tsukamoto T; Low BC; Sivaraman J
Oncotarget; 2016 Sep; 7(36):57943-57954. PubMed ID: 27462863
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA).
Thangavelu K; Chong QY; Low BC; Sivaraman J
Sci Rep; 2014 Jan; 4():3827. PubMed ID: 24451979
[TBL] [Abstract][Full Text] [Related]
6. Glutaminolysis Was Induced by TGF-β1 through PP2Ac Regulated Raf-MEK-ERK Signaling in Endothelial Cells.
Guo Y; Deng Y; Li X; Ning Y; Lin X; Guo S; Chen M; Han M
PLoS One; 2016; 11(9):e0162658. PubMed ID: 27612201
[TBL] [Abstract][Full Text] [Related]
7. Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
Zimmermann SC; Duvall B; Tsukamoto T
J Med Chem; 2019 Jan; 62(1):46-59. PubMed ID: 29969024
[TBL] [Abstract][Full Text] [Related]
8. Effect of lysine to alanine mutations on the phosphate activation and BPTES inhibition of glutaminase.
McDonald CJ; Acheff E; Kennedy R; Taylor L; Curthoys NP
Neurochem Int; 2015 Sep; 88():10-4. PubMed ID: 25510640
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
10. The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled.
Li Y; Ramachandran S; Nguyen TT; Stalnecker CA; Cerione RA; Erickson JW
J Biol Chem; 2020 Jan; 295(5):1328-1337. PubMed ID: 31871054
[TBL] [Abstract][Full Text] [Related]
11. A novel allosteric site employs a conserved inhibition mechanism in human kidney-type glutaminase.
Shankar S; Ramachandran S; Tulsian N; Radhakrishnan S; Jobichen C; Sivaraman J
FEBS J; 2023 May; 290(9):2437-2448. PubMed ID: 36259273
[TBL] [Abstract][Full Text] [Related]
12. Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.
Stalnecker CA; Erickson JW; Cerione RA
J Biol Chem; 2017 Apr; 292(15):6095-6107. PubMed ID: 28196863
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.
Shukla K; Ferraris DV; Thomas AG; Stathis M; Duvall B; Delahanty G; Alt J; Rais R; Rojas C; Gao P; Xiang Y; Dang CV; Slusher BS; Tsukamoto T
J Med Chem; 2012 Dec; 55(23):10551-63. PubMed ID: 23151085
[TBL] [Abstract][Full Text] [Related]
14. Full-length human glutaminase in complex with an allosteric inhibitor.
DeLaBarre B; Gross S; Fang C; Gao Y; Jha A; Jiang F; Song J J; Wei W; Hurov JB
Biochemistry; 2011 Dec; 50(50):10764-70. PubMed ID: 22049910
[TBL] [Abstract][Full Text] [Related]
15. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase.
Hartwick EW; Curthoys NP
J Enzyme Inhib Med Chem; 2012 Dec; 27(6):861-7. PubMed ID: 21999665
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of a novel glutaminase inhibitor.
Cederkvist H; Kolan SS; Wik JA; Sener Z; Skålhegg BS
FEBS Open Bio; 2022 Jan; 12(1):163-174. PubMed ID: 34698439
[TBL] [Abstract][Full Text] [Related]
17. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.
Ishii N; Harada N; Joseph EW; Ohara K; Miura T; Sakamoto H; Matsuda Y; Tomii Y; Tachibana-Kondo Y; Iikura H; Aoki T; Shimma N; Arisawa M; Sowa Y; Poulikakos PI; Rosen N; Aoki Y; Sakai T
Cancer Res; 2013 Jul; 73(13):4050-4060. PubMed ID: 23667175
[TBL] [Abstract][Full Text] [Related]
18. New insights into the molecular mechanisms of glutaminase C inhibitors in cancer cells using serial room temperature crystallography.
Milano SK; Huang Q; Nguyen TT; Ramachandran S; Finke A; Kriksunov I; Schuller DJ; Szebenyi DM; Arenholz E; McDermott LA; Sukumar N; Cerione RA; Katt WP
J Biol Chem; 2022 Feb; 298(2):101535. PubMed ID: 34954143
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Wan PT; Garnett MJ; Roe SM; Lee S; Niculescu-Duvaz D; Good VM; Jones CM; Marshall CJ; Springer CJ; Barford D; Marais R;
Cell; 2004 Mar; 116(6):855-67. PubMed ID: 15035987
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
